More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$347.73B
EPS
6.38
P/E ratio
22.1
Price to sales
5.97
Dividend yield
1.739%
Beta
1.790051
Previous close
$119.09
Today's open
$119.02
Day's range
$113.04 - $120.90
52 week range
$109.21 - $250.25
CEO
Michael D. Sicilia
Employees
141000
Headquarters
Austin, TX
Exchange
New York Stock Exchange
Shares outstanding
3.02B
Issue type
Common Stock
Technology
Software & IT Services
Oracle Has a Growth Opportunity That Goes Beyond Its Cloud Business
Oracle's stock has been crushed this year, and funding fears keep piling on. Yet healthcare software, a new data platform, and fast-growing multicloud revenue hint at a second engine that the market may be ignoring.
24/7 Wall Street • 10 hours ago

Oracle Warns Memory Shortages Could Constrain AI Infrastructure for Years
Oracle NYSE: ORCL expects memory capacity to remain a critical constraint on the expansion of artificial intelligence infrastructure for the next several years, CEO Clay Magouyrk told shareholders at the company's annual meeting.
MarketBeat • 7 hours ago

Big bets against AI debt, from CoreWeave to Oracle and the Mag 7, could soon hit the ETF market
Concerns about the debt being issued by artificial intelligence companies, particularly so-called neocloud companies, have been running high all year and pushing up credit default swap spreads. Tuttle Capital and Defiance have filed for ETFs that would use CDS to gain when credit risk worsens for AI-linked companies including CoreWeave and Oracle.
CNBC • 6 hours ago

Oracle's stock is ridiculously cheap even under the most gloomy scenarios, analyst says
Oracle's stock has taken a beating this year as investors worry about the company's role in the artificial-intelligence boom, but a Bernstein analyst thinks the stock looks cheap even if you were to assume the most difficult circumstances lie ahead.
Market Watch • 9 hours ago

Nvidia Just Said Demand Far Exceeds Supply. Oracle, 65% Below Its Peak, Still Trades Where It Sold $10 Billion of Stock
Oracle closed Tuesday at $115, 65% below its September 2025 peak and a cent above the low of the slide, before Nvidia's beat lifted it about 2.1% pre-market. In 27 years of prices the stock has lost more than half its value only once before, in 2000, and that fall took nearly 17 years to undo.
24/7 Wall Street • 12 hours ago

CoreWeave Falls 5% Despite NVIDIA Sticking to Its Financing Commitments; Nebius Dips, Oracle Holds Steady
A neocloud bounce faded at the open, and CoreWeave (NASDAQ:CRWV) took the biggest hit among its AI cloud peers. CoreWeave stock is at $47.41 in morning trading, down 5%.
24/7 Wall Street • 10 hours ago

New Oracle Primavera Cloud AI Capabilities Help Construction Teams Improve Project Planning and Risk Management
Addition of AI help assistant, risk library, and updated pull planning features enable project teams to find answers faster, apply lessons learned across projects, and prioritize work around key milestones AUSTIN, Texas, Nov. 18, 2026 /PRNewswire/ -- Oracle today announced new enhancements to Oracle Primavera Cloud (OPC) designed to help engineering and construction teams easily find product guidance, strengthen capital planning, risk management, and more effectively coordinate work around project milestones. With the new AI help assistant embedded in OPC, users can get real-time responses to everyday OPC questions such as "How do I assign a risk to an activity?
PRNewsWire • 12 hours ago

Oracle Life Sciences AI Agents Bring AI-Assisted Operational Intelligence and Coordination to Clinical Trials
New AI-assisted experience supports portfolio visibility, helps identify operational risks, and recommends next best actions AUSTIN, Texas, Nov. 18, 2026 /PRNewswire/ -- Oracle today introduced Oracle Life Sciences AI Agents, a new agentic experience designed to help life sciences organizations apply intelligence and AI-assisted coordination to enhance clinical trial operations. By bringing together insights from Oracle Life Sciences applications and supported third-party data sources, the agents are designed to help clinical trial teams identify operational issues, recommend appropriate actions for review and approval, and coordinate responses across clinical development workflows.
PRNewsWire • 12 hours ago

Oracle Stock Plunges 41% YTD Despite Cloud Strength: Hold or Fold?
Oracle ORCL shares have plunged 41% year to date (YTD), underperforming the Zacks Computer and Technology sector's growth of 2.5% and the Zacks Computer - Software industry's decline of 5.2%. The sell-off reflects investor anxiety over Oracle's aggressive AI infrastructure spending and negative free cash flow rather than any weakness in demand.
Zacks Investment Research • 8 hours ago

Michael Burry Closed His Oracle Puts, but Oracle Is Still Down 38% This Year. What Will It Take to Get ORCL Stock Back to $200?
Michael Burry has closed his bearish options trade against Oracle (NYSE:ORCL | ORCL Price Prediction), but the market's doubts about the company's AI spending haven't faded. Oracle stock is down 38% year to date (YTD) to $119.35, from a 2025 closing price of $192.35.
24/7 Wall Street • Nov 17, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Oracle Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.